Journals / MN Kardiyoloji / 2010 / Cilt: 17 - Sayı: 4

Compare anjiotensin receptor blockers in hypertension treatment depending on year 2010 data from reimburstment foundation view

Hipertansiyon tedavisinde anjiyotensin reseptör blokerlerinin geri ödeme kurumu açısından 2010 yılı verilerine göre karşılaştırılması

Pages
222–229
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Reimbursement foundation may be give priority to these two anjiotensin receptor blockers in hypertension treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Hypertension was the one of important risk factors in preventable cardiovascular risk factors.
📊
Key Findings & Data:The aim of this study is determine the cost effective anjiotensin reseptor blockers and combinations which have great percentage in Turkey antihypertension market.
💡
Conclusion & Impact:Reimbursement foundation may be give priority to these two anjiotensin receptor blockers in hypertension treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Hypertension was the one of important risk factors in preventable cardiovascular risk factors. The aim of this study is determine the cost effective anjiotensin reseptor blockers and combinations which have great percentage in Turkey antihypertension market. Material and Methods Effectiveness of anjiotensin receptor blockers and combinations were taken from a published meta-analysis. Costs were calculated depending on designed treatment protocol and incrementel cost effectiveness analysis was done. Results: Depending on designed treatment protocol losartan and combination were present the least costly treatment and 52 week treatment cost per patient was 423 TL. Losartan was comparable with irbesartan in incremental cost effectiveness analysis. Candesartan was dominated by losartan and valsartan was dominated by irbesartan. Conclusion: Losartan strategy was present the least costly treatment and irbesatan strategy was tepresent the most responders patients to treatment. Reimbursement foundation may be give priority to these two anjiotensin receptor blockers in hypertension treatment.

Özet

Amaç: Hipertansiyon, önlenebilir kardiyovasküler risk faktörleri içerisinde en önemli risk faktörlerindendir. Bu çalışmanın amacı Türkiye`deki antihipertansif ilaç pazarında büyük yer tutan anjiyotensin reseptör blokerleri ve kombinasyonları arasından en maliyet-etkili olanını belirlemektir. Gereç ve Yöntem: Anjiyotensin reseptör blokerleri ve kombinasyonlarının etkilililik verileri yayınlanmış bir meta-analizden alındı. Tasarlanan tedavi protokolüne göre maliyetler hesaplandı ve artırımlı maliyet etkililik analizi gerçekleştirildi. Bulgular: Tasarlanan tedavi protokolüne göre losartan ve kombinasyonu en uygun tedavi maliyeti sundu ve 52 haftalık hasta başına tedavi maliyeti 423 TL idi. Artırımlı maliyet etkililik analizi karşılaştırmasında losartan irbesartan ile karşılaştırılabilir çıkmıştır. Losartan kandesartana ve irbesartan valsartana üstün gelmiştir. Sonuç: Losartan stratejisi en düşük maliyetli tedaviyi sunmuş ve irbesartan stratejisi en yüksek tahmini hasta tedavi cevabını sunmuştur. Geri ödeme kurumları bu iki anjyiotensin reseptör blokerine hipertansiyon tedavisinde öncelik verebilir.

🔖

Cite This Article

KOÇKAYA, G., WERTHEİMER, A. I. (2010). Compare anjiotensin receptor blockers in hypertension treatment depending on year 2010 data from reimburstment foundation view. MN Kardiyoloji, Cilt: 17 - Sayı: 4, 222–229. https://ajindex.com/articles/297455

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. WHO Statistics [Internet]. [cited 2009 January 15]. Available from
  2. Stefanadis CI. The future of antihypertensive treatment: from myth to imminent reality. Hellenic J Cardiol. 2008; 49: 377-378 3. Theodoratou D., Maniadakis N., Fragoulakis V., Stamouli E. Analysis of Published Economic Evaluations of An gio - tensin Receptor Blockers Hellenic J Cardiol 2009;50:105- 118 4. Turkish Society of Cardiology [National Cardiology Health Politics], Turkish Society of Cardiology Antalya 2007 5. Center for Diseases Control and Prevention`s Statistics
  3. Özkara A, Turgut F, Selçoki Y, Kanbay M, Karakurt F, Tekin O et. al. Adherence of patients to antihypertensive medication and to health care centers. Yeni Tıp Dergisi 2008;25: 97-101 7. Turkey Health Ministery, [Primary Care Diagnose and Cure Guide], Ankara, 2003 www.saglik.gov.tr/aile/doc/ 1_basa mak_tıbbi_ted_kitap.pdf 8. Turkey Health Ministery Drug Pharmacy General Management, [Drug Price List], Ankara, 14.09.2010
  4. Conlin PR, Spence JD, Williams B, Ribeiro AB, Saito I, Benedict C, Bunt AM Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens. 2000;13 (4 Pt 1):418-26 10. Briggs A. H Handling Uncertainty in Cost-Effectiveness Models PharmacoEconomics, Volume 17, Number 5, May 2000, pp. 479-500 (22
  5. National Heart, Lung and Blood Institute,Framingham Heart Study, Boston,2009 http://www.framinghamheartstudy. org 12. Simons WR. Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan. Pharmacoeconomics. 2003; 21 (1):61-74
  6. Theodoratou D, Maniadakis N, Fragoulakis V, Stamouli E Analysis of published economic evaluations of angiotensin receptor blockers. Hellenic J Cardiol. 2009 Mar- Apr;50 (2): 105-18 14. Doğan A. Akçay S. [The effect of inhibition of renin-angiotensin system on cardioversion success and recurrences of atrial fibrillation] Anadolu Kardiyol Derg 2009; 9: 505-11 15. Yorgun H., Atalar E. Treatment of Hypertension According to New Guidelines Turkiye Klinikleri J Cardiol-Special Topics 2009;2 (4):21-30